Redmile Group LLC bought a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 1,261,427 shares of the company’s stock, valued at approximately $40,189,000. 4D Molecular Therapeutics makes up 1.5% of Redmile Group LLC’s investment portfolio, making the stock its 25th largest position.
Several other large investors also recently bought and sold shares of FDMT. Bfsg LLC purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth $30,000. Allspring Global Investments Holdings LLC raised its stake in 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in 4D Molecular Therapeutics by 359.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock worth $100,000 after acquiring an additional 3,873 shares during the period. Daiwa Securities Group Inc. lifted its position in 4D Molecular Therapeutics by 23.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock worth $119,000 after acquiring an additional 1,110 shares during the period. Finally, Entropy Technologies LP acquired a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $239,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. BMO Capital Markets decreased their target price on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, July 18th. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of 4D Molecular Therapeutics in a report on Wednesday, July 17th. Jefferies Financial Group increased their price objective on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Barclays began coverage on shares of 4D Molecular Therapeutics in a research report on Monday, April 15th. They set an “overweight” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 22nd. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $43.63.
Insider Buying and Selling
In related news, CEO David Kirn sold 12,930 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $23.10, for a total value of $298,683.00. Following the transaction, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO David Kirn sold 12,930 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $21.36, for a total transaction of $90,737.28. Following the sale, the insider now directly owns 1,737 shares in the company, valued at approximately $37,102.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,597 shares of company stock valued at $821,939. 7.30% of the stock is owned by corporate insiders.
4D Molecular Therapeutics Stock Performance
Shares of 4D Molecular Therapeutics stock traded down $1.23 on Monday, hitting $17.12. The company’s stock had a trading volume of 509,249 shares, compared to its average volume of 957,330. The company has a market capitalization of $885.10 million, a price-to-earnings ratio of -7.02 and a beta of 2.84. 4D Molecular Therapeutics, Inc. has a 1 year low of $9.44 and a 1 year high of $36.25. The firm has a fifty day moving average price of $22.42 and a 200-day moving average price of $24.91.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.44 million. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current year.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More
- Five stocks we like better than 4D Molecular Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- Survey: Top 175 Fittest Retirement Locations in America
- Investing in Commodities: What Are They? How to Invest in Them
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Best Stocks Under $5.00
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report).
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.